MedPath

Nerandomilast: A Novel PDE4B Inhibitor Shows Promise in Treating Idiopathic Pulmonary Fibrosis

• Nerandomilast (BI 1015550) is a potent and selective phosphodiesterase 4B (PDE4B) inhibitor demonstrating potential for treating idiopathic pulmonary fibrosis (IPF). • The drug's mechanism of action targets the reduction of inflammation and fibrosis, key pathological features of IPF, offering a novel therapeutic approach. • Preclinical and early clinical data suggest nerandomilast has a favorable safety profile and demonstrates target engagement, warranting further investigation. • Nerandomilast's oral bioavailability and demonstrated clinical potential position it as a promising candidate in the evolving treatment landscape for IPF.

Nerandomilast (BI 1015550), a selective phosphodiesterase 4B (PDE4B) inhibitor, is emerging as a promising therapeutic agent for idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive fibrotic lung disease with limited treatment options and a poor prognosis, affecting approximately 13 to 20 per 100,000 adults worldwide. Nerandomilast's mechanism of action focuses on reducing inflammation and fibrosis, addressing key pathological aspects of IPF.

Mechanism of Action

Nerandomilast inhibits PDE4B, an enzyme that regulates the levels of intracellular cyclic adenosine monophosphate (cAMP). By inhibiting PDE4B, nerandomilast increases cAMP levels in immune and structural cells within the lung. This increase in cAMP leads to a reduction in the release of pro-inflammatory mediators and profibrotic factors, thereby mitigating inflammation and fibrosis. The selectivity for PDE4B over other PDE isoforms is crucial to minimize potential side effects, enhancing its therapeutic potential.

Clinical Potential

Preclinical studies have demonstrated that nerandomilast significantly reduces lung fibrosis in animal models of IPF. Early clinical trials have shown that nerandomilast is well-tolerated and exhibits dose-dependent target engagement in patients. These findings support further investigation into its efficacy in larger, randomized controlled trials. The oral bioavailability of nerandomilast also offers a convenient administration route for patients.

Current Treatment Landscape and Unmet Needs

Currently approved treatments for IPF, such as pirfenidone and nintedanib, slow disease progression but do not halt or reverse fibrosis. These treatments are also associated with significant side effects, highlighting the need for new therapies with improved efficacy and safety profiles. Nerandomilast represents a novel approach to treating IPF by targeting PDE4B, potentially offering a more targeted and effective treatment option. Further clinical trials are underway to evaluate the long-term efficacy and safety of nerandomilast in patients with IPF.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

US FDA Accepts NDA Filing for BI's Nintedanib

The US FDA has accepted Boehringer Ingelheim's New Drug Application for nintedanib, granting it Priority Review for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease with no current FDA-approved treatments.

Chiesi Farmaceutici's Inhaled PI3Kδ Inhibitor Suggests Target Unsuitability for COPD Management

Chiesi Farmaceutici disclosed CHF-6523, an inhaled PI3Kδ inhibitor, suggesting challenges in targeting PI3Kδ for COPD treatment.
AstraZeneca and Mitsubishi Tanabe are developing AZD4144, a clinical compound currently in Phase I trials in healthy volunteers.

Inebilizumab Shows Promise in Reducing Flares of IgG4-Related Disease

A Phase 3 clinical trial demonstrated that inebilizumab significantly reduced the risk of disease flares in patients with IgG4-related disease.
The study found an 87% reduction in flare risk among patients treated with inebilizumab compared to those receiving a placebo.

NLRP3 Inhibitors Show Promise Across Autoimmune, Neurodegenerative, and Metabolic Diseases

The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions.
NLRP3 inhibitors are being explored for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as metabolic conditions such as NASH.

Chiesi's Inhaled PI3Kδ Inhibitor CHF-6523 Shows Limited Clinical Benefit in COPD

Chiesi Farmaceutici's CHF-6523, a selective PI3Kδ inhibitor, is designed for inhaled delivery to treat COPD by reducing lung inflammation.
The development of CHF-6523 focused on optimizing its permeability, solubility, and suitability for dry powder inhalation.

Io Therapeutics' IRX4204 Shows Promise in Combating Neurodegeneration Linked to Normal Aging

Io Therapeutics presented data on IRX4204, a Phase II RXR agonist, at the FASEB conference, highlighting its potential to prevent and treat neurodegeneration associated with normal aging.
Studies reveal IRX4204's ability to inhibit brain inflammation by reducing IL-6 production and modulating Treg and Th17 cell activity, addressing key aspects of neuro-inflammaging.

Nerandomilast Shows Promise in Phase 3 Trial for Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim's nerandomilast met its primary endpoint in the Phase 3 FIBRONEER-IPF trial, demonstrating improved lung function in IPF patients.
The trial is the first in a decade to meet its primary endpoint, offering hope for a new treatment option for this progressive disease.

Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-IPF Trial

Boehringer Ingelheim's nerandomilast met the primary endpoint in the Phase III FIBRONEER-IPF trial, showing a significant change in Forced Vital Capacity (FVC) at week 52 compared to placebo.
The FIBRONEER-IPF trial, the largest IPF trial to date, recruited patients from over 330 sites across more than 30 countries, demonstrating broad global participation.

Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-IPF Trial for Idiopathic Pulmonary Fibrosis

Nerandomilast met the primary endpoint in the FIBRONEER-IPF trial, demonstrating a statistically significant absolute change from baseline in Forced Vital Capacity (FVC) at week 52 compared to placebo.
The FIBRONEER-IPF trial, involving over 1177 patients across more than 30 countries, stands as the largest IPF trial conducted to date.

Reference News

[1]
A PDE4B Inhibitor With Demonstrated Clinical Potential in Treating IPF
drughunter.com · Sep 13, 2024

NT-0796, NodThera's NLRP3 inflammasome inhibitor, is in a Ph. Ib/IIa trial for atherosclerotic cardiovascular diseases i...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy